Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 37Withdrawn 5Unknown 2Recruiting 2Active not recruiting 2Terminated 1Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 10Other hematologic neoplasm 9Genitourinary 7CNS 6Sarcoma 5Myeloid 4Gastrointestinal 4Gynecologic 3Thoracic 2Plasma cell 2Other solid neoplasm 2Breast 2Dermatologic 1

Conditions

Melanoma 1

Interventions

pembrolizumab 58Cyclophosphamide 53Ipilimumab 52Nivolumab 44aldesleukin 35Interleukin-2 26fludarabine phosphate 22fludarabine 21Vemurafenib 20Temozolomide 19Radiotherapy 18dabrafenib 15trametinib 12Radiosurgery 11CTLA-4 Antigen 11Filgrastim 10Dacarbazine 10spartalizumab 9cobimetinib 9binimetinib 9atezolizumab 9Biopsy 9poly ICLC 8Paclitaxel 8Antilymphocyte Serum 8encorafenib 7avelumab 7Rituximab 7Introns 7romidepsin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × sargramostim × Dermatologic × Clear all
NCT00006113 2014-05-22

Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma

University of Southern California

Phase 2 Terminated
25 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡